
Our Board of Directors bring diverse experience and significant expertise to guide our path forward.
We work together to develop breakthrough therapies to treat cancer through improving the immune response.
Our leadership team combine biotech and pharma expertise in immuno-oncology, clinical and corporate strategy to manage the activities of iTeos both in Europe and USA in order to develop and deliver the next generation of cancer immunotherapies.
iTeos’ Scientific Advisory Board board provides an external scientific review of R&D activities and assists us in making significant scientific judgments related to R&D activities and portfolio management and prioritization.